Anti-thrombotic therapy for atrial fibrillation in patients with chronic kidney disease: Current views

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Non-valvular atrial fibrillation (AF) affects approximately one-third of patients with chronic kidney disease (CKD).
• CKD, especially advanced stages, increases risks of thromboembolism and major bleeding in AF patients already prone to stroke and bleeding from anticoagulation.
• Warfarin's efficacy and safety in advanced CKD patients, including those on hemodialysis, remain uncertain due to conflicting study results.

Purpose of the Study:

• To review the current understanding of antithrombotic therapy in patients with AF and CKD.
• To evaluate the effectiveness and safety of direct oral anticoagulants (DOACs) compared to warfarin in this patient population.
• To identify knowledge gaps regarding antithrombotic treatment in advanced CKD patients with AF.

Main Methods:

• Literature review of studies comparing warfarin and DOACs in AF patients with varying degrees of CKD.
• Analysis of data regarding thromboembolic events (ischemic stroke, systemic embolism) and major bleeding.
• Focus on studies including patients with moderate (Stage III) and advanced CKD.

Main Results:

• DOACs appear as effective or more effective than warfarin in preventing stroke and embolism in patients with Stage III CKD.
• Apixaban and edoxaban, with dose adjustments, demonstrate a lower risk of major bleeding compared to warfarin.
• Limited data exists for DOACs in patients with advanced CKD, including those on hemodialysis.

Conclusions:

• DOACs offer a potentially safer and effective alternative to warfarin for stroke prevention in AF patients with moderate CKD.
• Significant gaps remain in understanding the optimal antithrombotic strategy for AF patients with advanced CKD.
• Exclusion of advanced CKD patients from major clinical trials limits evidence-based treatment recommendations.